MAZE
Maze Therapeutics Inc.

79
Mkt Cap
$2.18B
Volume
490,857.00
52W High
$49.25
52W Low
$6.71
PE Ratio
-20.09
MAZE Fundamentals
Price
$47.23
Prev Close
$45.30
Open
$45.59
50D MA
$43.00
Beta
1.01
Avg. Volume
396,215.50
EPS (Annual)
$0.0778
P/B
5.74
Rev/Employee
$1.34M
Loading...
Loading...
News
all
press releases
Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Rating of "Buy" from Analysts
Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been assigned a consensus rating of "Buy" from the eleven analysts that are presently covering the firm, MarketBeat.com reports...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
Key PointsChief Medical Officer Harold Bernstein exercised 15,000 shares, which were sold immediately for a total transaction value of approximately $690,300 on Feb. 2, 2026...
Nasdaq News: Markets·10d ago
News Placeholder
Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit
Maze Therapeutics (NASDAQ:MAZE) is advancing a genetics-driven approach to drug development, using human genetic analyses to identify gene variants linked to disease and then applying those insights...
MarketBeat·12d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·19d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 15,000 Shares
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 15,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of...
MarketBeat·21d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month High - Should You Buy?
Maze Therapeutics (NASDAQ:MAZE) Hits New 12-Month High - Time to Buy...
MarketBeat·22d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $332,025.00 in Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction dated Thursday, January 29th. The stock was sold at an...
MarketBeat·23d ago
News Placeholder
Strs Ohio Decreases Stake in Maze Therapeutics, Inc. $MAZE
Strs Ohio cut its position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) by 61.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and...
MarketBeat·25d ago
News Placeholder
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock
Key PointsAmy Bachrodt exercised 5,000 shares and immediately sold them for approximately $227,612 on Jan. 22, 2026...
Nasdaq News: Markets·25d ago
News Placeholder
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 5,000 Shares of Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an...
MarketBeat·30d ago
<
1
2
...
>

Latest MAZE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.